Daxor Sets June 24 Annual Meeting for Director Election, Auditor Ratification

TL;DR

**DAXOR's upcoming shareholder meeting is a standard governance check, vote FOR the board and auditors to maintain stability.**

AI Summary

DAXOR CORP filed a Definitive Proxy Statement (DEF 14A) on June 6, 2025, outlining the agenda for its Annual Meeting of Stockholders to be held on June 24, 2025, at the Nasdaq Stock Exchange in New York. The primary purposes of the meeting are to elect a board of six directors, each for a one-year term, and to ratify the appointment of Bush & Associates, CPA, as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The Board of Directors explicitly recommends a vote "FOR ALL NOMINEES" for Proposal 1 and "FOR" the ratification of Bush & Associates in Proposal 2. Shareholders of record as of May 19, 2025, are entitled to vote, with each share granting one vote. The filing does not disclose specific revenue or net income figures, nor does it detail key business changes or strategic outlooks beyond the standard annual meeting proposals. Risks are not explicitly quantified or detailed in this specific DEF 14A filing, which focuses solely on meeting logistics and proposals.

Why It Matters

This DEF 14A filing is crucial for investors as it details the upcoming governance decisions at DAXOR CORP, including the election of its six-member board and the ratification of its auditor, Bush & Associates, CPA. These decisions directly impact the company's strategic direction, financial oversight, and overall accountability to shareholders. For employees and customers, a stable and well-governed company ensures operational continuity and confidence. In the competitive landscape, strong governance, as reflected in these annual decisions, can enhance investor trust and potentially influence market perception compared to peers with less transparent or stable leadership structures.

Risk Assessment

Risk Level: low — The risk level is low because this DEF 14A filing is a routine proxy statement for an annual meeting, primarily addressing the election of directors and the ratification of auditors. There are no indications of contentious proposals, significant corporate actions, or financial distress within the document itself. The proposals are standard governance items, not high-risk strategic shifts.

Analyst Insight

Investors should review the biographies of the six director nominees and the qualifications of Bush & Associates, CPA, to ensure alignment with their investment thesis. Given the Board's recommendations, a vote 'FOR' both proposals is the path of least resistance, but informed shareholders should still exercise their right to vote by June 24, 2025.

Key Numbers

• 6 — Number of directors to be elected (Each to serve for a term of one year)
• 1 — Term length for elected directors (One year term for each director)
• 1 — Votes per share (Shareholders are entitled to one vote per share)
• 2025 — Fiscal year for auditor appointment (Bush & Associates, CPA appointed for year ending December 31, 2025)
• 10:45 AM — Meeting start time (Eastern Daylight Time on June 24, 2025)

Key Players & Entities

• DAXOR CORP (company) — Registrant and filer of DEF 14A
• Robert J. Michel (person) — Corporate Secretary of DAXOR CORP
• Bush & Associates, CPA (company) — Independent registered public accounting firm for DAXOR CORP
• Nasdaq Stock Exchange (company) — Location of DAXOR CORP's Annual Meeting
• SEC (regulator) — Securities and Exchange Commission
• May 19, 2025 (date) — Record date for stockholders entitled to vote
• June 24, 2025 (date) — Date of DAXOR CORP's Annual Meeting of Stockholders
• December 31, 2025 (date) — End of fiscal year for which Bush & Associates, CPA will serve
• New York, New York (location) — City where Annual Meeting will be held
• 350 Fifth Avenue, Suite 4740, New York, NY 10118 (location) — DAXOR CORP's business address

FAQ

Industry Context

Daxor Corp operates within the healthcare technology sector, specifically focusing on diagnostic instrumentation. The industry is characterized by ongoing innovation in medical devices, stringent regulatory oversight from bodies like the FDA, and a competitive landscape with both established players and emerging companies. Trends include the increasing demand for point-of-care diagnostics and the integration of AI in medical devices.

Regulatory Implications

As a publicly traded company, Daxor Corp is subject to SEC regulations governing proxy solicitations and corporate governance. The appointment and ratification of an independent auditor are critical compliance requirements. Furthermore, as a medical device company, Daxor is subject to health and safety regulations from agencies like the FDA, which can impact product development, manufacturing, and market access.

What Investors Should Do

1. Review the DEF 14A filing thoroughly.
2. Vote on Proposal 1 (Director Elections).
3. Vote on Proposal 2 (Auditor Ratification).
4. Submit proxy in advance of the meeting.

Key Dates

• 2025-05-19: Record date for determining stockholders entitled to vote at the Annual Meeting — Establishes the list of shareholders eligible to participate in the voting process for the upcoming meeting.
• 2025-06-06: Filing of Definitive Proxy Statement (DEF 14A) — Provides shareholders with detailed information regarding the agenda and proposals for the Annual Meeting.
• 2025-06-24: Annual Meeting of Stockholders — Key date for shareholders to vote on director elections and auditor ratification.
• 2025-12-31: Fiscal year end for which the independent auditor is appointed — Defines the period for which Bush & Associates, CPA will provide audit services.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC, providing detailed information about matters to be voted on at a company's annual or special meeting of shareholders. (This document outlines the agenda for Daxor Corp's annual meeting, including director elections and auditor ratification.)

Independent Registered Public Accounting Firm

An external audit firm hired by a company to provide an independent opinion on the fairness of its financial statements. (The appointment of Bush & Associates, CPA is a key proposal for shareholder ratification at the annual meeting.)

Proxy Statement

A document that the SEC requires companies to provide to shareholders before a shareholder meeting, containing information about the meeting agenda, board nominees, and other relevant details. (This is the primary document informing shareholders about the proposals and how to vote.)

Board of Directors

A group of individuals elected by shareholders to oversee the management of a company and represent shareholder interests. (The election of six directors for one-year terms is a primary agenda item for the annual meeting.)

Ratify

To formally approve or confirm a decision or action, typically by a vote. (Shareholders are asked to ratify the appointment of the company's independent auditor.)

Year-Over-Year Comparison

This filing is a standard DEF 14A for an annual meeting and does not provide comparative financial data or strategic shifts from a previous filing. It focuses on the upcoming meeting's agenda, including the election of six directors and the ratification of the independent auditor for the fiscal year ending December 31, 2025. No specific financial performance metrics or changes in risk factors are detailed within this proxy statement itself.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 6, 2025 by Robert J. Michel regarding DAXOR CORP (DXR).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR